When was Zantac recalled?
In April of 2020, the FDA announced that all Zantac brand and its generic equivalent heartburn drugs, both prescription and over-the-counter versions, should be immediately pulled from the market. Why was Zantac pulled off the Market? On September 13, 2019, the U.S. Food and Drug Administration (FDA) reported the discovery of the carcinogenic contaminant N-nitrosodimethylamine (NDMA) in Zantac (ranitidine). NDMA was found in Zantac and its generic equivalents at levels beyond what is considered safe. Scientific research has shown that, when ranitidine comes in contact with water, it creates a chemical reaction that causes the formation of NDMA. Studies have linked the NDMA to cancer in animals and humans. What is NMDA? A carcinogenic contaminant N-nitrosodimethylamine (NDMA) is a carcinogenic contaminant that has been linked to cancer in patients that have taken the drug. NDMA is a volatile, combustible, yellow, oily liquid nitrosamine with a faint characteristic odor. The chemical decomposes when exposed to light and emits toxic fumes when heated. NDMA is used primarily in research labs induce tumors in experimental animals. In 2014, the EPA issued a statement about NDMA contamination in drinking water. What are the lawsuits about? In the current litigation, the plaintiffs allege that the manufacturers placed on the market a dangerous product and failed to warn consumers of the serious risks and side effects. The main manufacturers of Zantac include: Sanofi, Boehringer Ingelheim, and GSK. What cancers and other diseases are linked to Zantac (Ranitidine)?
Bladder
Colon
Pancreatic
Esophageal
Kidney
Liver
Stomach/Gastric
Breast
Lung
Prostate
Do you or someone you know take Zantac and now have cancer? Contact the Law Office of Darren Wolf, P.C. today.